LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...

Inspire Medical Systems topped Q3 expectations, signaling continued market strength and innovation.

Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe ...

The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA ... data to the U.S. Food and Drug Administration (FDA) ...

Inspire Medical Systems shares are up today on third-quarter results that came in ahead of the consensus forecast.

such as sleep apnea. Share on Pinterest Trazodone is a prescription medication approved by the Food and Drug Administration (FDA) for depression. One of its key actions is regulating the ...

Among potential surgeries for sleep apnea is UPPP (uvulopalatopharyngoplasty) surgery, which involves removing part of the ...

Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...

Do you suffer from sleep apnea and long for a peaceful night’s sleep and solution to your snoring? Holy Cross Medical Group pulmonologist Ronald Scott, M.D. will speak about Inspire®, an FDA-approved ...